Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of intravenous
administration of intermittent doses of levosimendan (infusions of 0,2 μg/kg/min, of
levosimendan or placebo, without bolus, for 6 hours every 2 weeks) compared to placebo in
ambulatory patients with advanced chronic heart failure.